Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA date (NASDAQ:CAPR)
· seekingalpha.com
Capricor's Deramiocel FDA decision is targeted for Nov.
Earnings Call Insights Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA date Nov 10, 2026, 9:42 PM ET Capricor Thera...